Файловый архив студентов. Файловый архив студентов.
1327 вузов, 5482 предметов.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4434_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
58 Мб
Скачать
☆
►Содержание►
478
B. H. Siddiquee
cases. Laryngoscope. 1984;94(7):942–5. https://doi.
org/10.1288/00005537- 198407000- 00015.
51. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1972;29(6):1446–9. https://doi.org/10.1002/1097-
0142(197206)29:6<1446::aid- cncr2820290604>3.0 .co;2- c.
52. Shah JP.Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodiges­tive tract. Am J Surg. 1990;160(4):405–9. https://
doi.org/10.1016/s0002- 9610(05)80554- 9.
53. Shah JP, Candela FC, Poddar AK. The pat­terns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 1990;66(1):109–13. https://doi.org/10.1002/1097-
0142(19900701)66:1<109::aid- cncr2820660120>3.
0.co;2- a.
54. Lim Y, Song M, Kim S, Kim K, Choi E.Preserving level IIb lymph nodes in elective supraomohy­oid neck dissection for oral cavity squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130(9):1088. https://doi.org/10.1001/
archotol.130.9.1088.
55. Pandey M, Karthikeyan S, Joshi D, Kumar M, Shukla M.Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cav­ity. World J Surg Oncol. 2018;16(1) https://doi.
org/10.1186/s12957- 018- 1518- z.
56. Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “senti­nel node” in cancer of the parotid. Cancer. 1960;13:77–8. https://doi.org/10.1002/1097-
0142(196001/02)13:1<77::aid- cncr2820130114>3.
0.co;2- d.
57. Shoaib T, Soutar DS, MacDonald DG, et al. The accuracy of head and neck carcinoma sentinel lymph node biopsy in the clinically N0 neck. Cancer. 2001;91(11):2077–83. https://doi.org/10.1002/1097-
0142(20010601)91:11<2077::aid­cncr1235>3.0.co;2- e.
58. Lombardi CP, Raffaelli M, Princi P, De Crea C, Bellantone R. Minimally invasive video-assisted functional lateral neck dissection for meta­static papillary thyroid carcinoma. Am J Surg. 2007;193(1):114–8. https://doi.org/10.1016/j.
amjsurg.2006.02.024.
59. Terris DJ, Monfared A, Thomas A, Kambham N, Sáenz Y. Endoscopic selective neck dissection in a porcine model. Arch Otolaryngol Head Neck Surg. 2003;129(6):613–7. https://doi.org/10.1001/
archotol.129.6.613.
60. Malloy KM, Cognetti DM, Wildemore BM, et al. Feasibility of endoscopic sentinel node biopsy in the porcine neck. Otolaryngol Head Neck Surg. 2007;136(5):806–10. https://doi.org/10.1016/j.
otohns.2006.11.025.
61. Guttman MR. Rehabilitation of voice in laryngec­tomized patients. Arch Otolaryngol. 1932;15:478–9.
62. Nijdam H, Annyas A, Schutte H, Leever H.A new prosthesis for voice rehabilitation after laryngec­tomy. Arch Otorhinolaryngol. 1982;237:27–9.
63. Jebria AB, Henry C, Petit J, Gioux M, Devars F, Traissac L. Physical and aerodynamic features of the Bordeaux voice prosthesis. Artif Organs. 2008;11(5):383–7. https://doi.org/10.1111/j.1525-
1594.1987.tb00949.x.
64. Hilgers F, Schouwenburg P. A new low­resistance, self-retaining prosthesis (Provox) for voice rehabilitation after total laryngectomy. Laryngoscope. 1990;100(11):1202–7. https://doi.
org/10.1288/00005537- 199011000- 00014.
65. Hilgers F, Cornelissen M, Balm A. Aerodynamic characteristics of the Provox low-resistance indwell­ing voice prosthesis. Eur Arch Otorhinolaryngol. 1993;250(7) https://doi.org/10.1007/bf00180379.
66. Pressman JJ, Simon MB, Monell CM. Anatomic studies related to the dis­semination of cancer of the larynx. Cancer. 1961;14:1131–8. https://doi.org/10.1002/1097-
0142(196109/10)14:5<1131::aid- cncr2820140536>
3.0.co;2- #.
67. Alonso JM. Conservative surgery of cancer of the larynx. Trans Am Acad Ophthalmol Otolaryngol. 1947;51:633–42.
68. Majer EH, Rieder W. Technique de laryngectomie permetant de conserver la permeabilite. Ann Otol Rhinol Laryngol. 1959;76:677–81.
69. Ambrosch P. The role of laser microsurgery in the treatment of laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg. 2007;15(2):82–8. https://doi.
org/10.1097/MOO.0b013e3280147336.
70. Genden EM, Ferlito A, Silver CE, et al. Evolution of the management of laryngeal cancer. Oral Oncol. 2007;43(5):431–9. https://doi.org/10.1016/j.
oraloncology.2006.08.007.
71. Weinstein GS, O’Malley BW Jr, Snyder W, Hockstein NG. Transoral robotic surgery: supra­glottic partial laryngectomy. Ann Otol Rhinol Laryngol. 2007;116(1):19–23. https://doi.
org/10.1177/000348940711600104.
72. Weinstein G, O’Malley BW Jr, Hockstein NG. Transoral robotic surgery: supraglottic lar­yngectomy in a canine model. Laryngoscope. 2005;115(7):1315–9. https://doi.org/10.1097/01.
mlg.0000170848.76045.47.
73. O’Malley B, Weinstein G, Hockstein N. Transoral robotic surgery (TORS): glottic microsurgery in a canine model. J Voice. 2006;20(2):263–8. https://
doi.org/10.1016/j.jvoice.2005.10.004.
74. National Comprehensive Cancer Network. NCCN practice guidelines in oncology: head and neck can­cers. 2013. http://www.nccn.org/professionals/phy-
sician_gls/f_guidelines.asp.
75. Pederson A, Salama J, Witt M, etal. Concurrent che­motherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol. 2011;34(4):356–61.
https://doi.org/10.1097/coc.0b013e3181e8420b.
19 Updates andControversies intheManagement ofHead andNeck Malignancy
479
76. Bedwinek J, Shukovsky L, Fletcher G, Daley T. Osteonecrosis in patients treated with deni­tive radiotherapy for squamous cell carcinomas of the oral cavity and naso- and oropharynx. Radiology. 1976;119(3):665–7. https://doi.
org/10.1148/119.3.665.
77. Loree T, Strong E. Signicance of positive mar­gins in oral cavity squamous carcinoma. Am J Surg. 1990;160(4):410–4. https://doi.org/10.1016/
s0002- 9610(05)80555- 0.
78. Cooper J, Pajak T, Forastiere A, etal. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44. https://doi.
org/10.1056/NEJMoa032646.
79. Montero PH, Patel SG. Cancer of the oral cav­ity. Surg Oncol Clin N Am. 2015;24(3):491–508.
https://doi.org/10.1016/j.soc.2015.03.006.
80. Farah C, Dalley A, Nguyen P, etal. Improved sur­gical margin denition by narrow band imaging for resection of oral squamous cell carcinoma: a prospective gene expression proling study. Head Neck. 2015;38(6):832–9. https://doi.org/10.1002/
hed.23989.
81. Vu A, Farah C. Narrow band imaging: clinical applications in oral and oropharyngeal cancer. Oral Dis. 2016;22(5):383–90. https://doi.org/10.1111/
odi.12430.
82. Schmalbach C, Chepeha D, Giordano T, et al. Molecular proling and the identication of genes associated with metastatic oral cavity/pharynx squa­mous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130(3):295. https://doi.org/10.1001/
archotol.130.3.295.
83. Gourin C, Boyce B, Vaught C, Burkhead L, Podolsky R.Effect of comorbidity on post-treatment quality of life scores in patients with head and neck squamous cell carcinoma. Laryngoscope. 2009;119(5):907–14.
https://doi.org/10.1002/lary.20199.
84. Ang K, Harris J, Wheeler R, etal. Human papillo­mavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. https://doi.
org/10.1056/NEJMoa0912217.
85. Mydlarz W, Chan J, Richmon J. The role of sur­gery for HPV-associated head and neck cancer. Oral Oncol. 2015;51:305–13. https://doi.org/10.1016/j.
oraloncology.2014.10.005.
86. Tateya I, Shiotani A, Satou Y, et al. Transoral sur­gery for laryngo-pharyngeal cancer—the paradigm shift of the head and cancer treatment. Auris Nasus Larynx. 2016;43(1):21–32. https://doi.org/10.1016/j.
anl.2015.06.013.
87. Kass J, Pool C, Teng M, Miles B, Genden E.Initial experience using transoral robotic surgery for advanced-stage (T3) tumors of the head and neck. Int J Radiat Oncol Biol Phys. 2016;94(4):899.
https://doi.org/10.1016/j.ijrobp.2015.12.106.
88. Weinstein G, O’Malley B, Cohen M, Quon H. Transoral robotic surgery for advanced oropha­ryngeal carcinoma. Arch Otolaryngol Head Neck
Surg. 2010;136(11):1079. https://doi.org/10.1001/
archoto.2010.191.
89. Hinni M, Nagel T, Howard B.Oropharyngeal cancer treatment: the role of transoral surgery. Curr Opin Otolaryngol Head Neck Surg. 2015;23(2):132–8.
https://doi.org/10.1097/MOO.0000000000000143.
90. Kelly K, Johnson-Obaseki S, Lumingu J, Corsten M.Oncologic, functional and surgical outcomes of primary Transoral Robotic Surgery for early squa­mous cell cancer of the oropharynx: a systematic review. Oral Oncol. 2014;50(8):696–703. https://
doi.org/10.1016/j.oraloncology.2014.04.005.
91. Reynolds L, Rigby M, Trites J, Hart R, Taylor S. Outcomes of transoral laser microsurgery for recurrent head and neck cancer. J Laryngol Otol. 2013;127(10):982–6. https://doi.org/10.1017/
S0022215113001953.
92. White H, Ford S, Bush B, et al. Salvage surgery for recurrent cancers of the oropharynx. JAMA Otolaryngol Head Neck Surg. 2013;139(8):773.
https://doi.org/10.1001/jamaoto.2013.3866.
93. Dallan I, Castelnuovo P, Vicini C, Tschabitscher M.The natural evolution of endoscopic approaches in skull base surgery: robotic-assisted surgery? Acta Otorhinolaryngol Ital. 2011;31(6):390–4.
94. Mercante G, Ruscito P, Pellini R, Cristalli G, Spriano G. Transoral robotic surgery (TORS) for tongue base tumours. Acta Otorhinolaryngol Ital. 2013;33(4):230–5.
95. Mirimanoff R, Wang C, Doppke K. Combined surgery and postoperative radiation therapy for advanced laryngeal and hypopharyngeal carcinomas. Int J Radiat Oncol Biol Phys. 1985;11(3):499–504.
https://doi.org/10.1016/0360- 3016(85)90180- 4.
96. Hoffman H, Karnell L, Shah J, et al. Hypopharyngeal cancer patient care evaluation. Laryngoscope. 1997;107:1005–17. https://doi.
org/10.1097/00005537- 199708000- 00001.
97. Braendstrup P. Lehrbuch der Augenheilkunde.
2. AufL. 1954. Karger, Basel. Acta Ophthalmol. 2009;32(1):95–6. https://doi.org/10.1111/j.1755-
3768.1954.tb07677.x.
98. Chu P, Chang S.Reconstruction of the hypopharynx after surgical treatment of squamous cell carcinoma. J Chin Med Assoc. 2009;72(7):351–5. https://doi.
org/10.1016/s1726- 4901(09)70386- 7.
99. Disa J, Pusic A, Hidalgo D, Cordeiro P.Microvascular reconstruction of the hypopharynx: defect classica­tion, treatment algorithm, and functional outcome based on 165 consecutive cases. Plast Reconstr Surg. 2003;111(2):652–60. https://doi.org/10.1097/01.
prs.0000041987.53831.23.
100. Ho M, Houghton L, Gillmartin E, etal. Outcomes following pharyngolaryngectomy reconstruction with the anterolateral thigh (ALT) free ap. Br J Oral Maxillofac Surg. 2012;50(1):19–24. https://doi.
org/10.1016/j.bjoms.2010.10.004.
101. Yu P, Hanasono M, Skoracki R, et al. Pharyngoesophageal reconstruction with the antero­lateral thigh ap after total laryngopharyngec-
480
B. H. Siddiquee
tomy. Cancer. 2010;116(7):1718–24. https://doi.
org/10.1002/cncr.24947.
102. Kim V, Chapman W, Albrecht R, etal. Early experience with telemanipulative robot-assisted laparoscopic cholecystectomy using Da Vinci. Surg Laparosc Endosc Percutan Tech. 2002;12(1):33–40. https://
doi.org/10.1097/00129689- 200202000- 00006.
103. Moore E, Olsen K, Kasperbauer J.Transoral robotic surgery for oropharyngeal squamous cell carcinoma: a prospective study of feasibility and functional outcomes. Laryngoscope. 2009;119(11):2156–64.
https://doi.org/10.1002/lary.20647.
104. Boudreaux B, Rosenthal E, Magnuson J, et al. Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg. 2009;135(4):397. https://doi.org/10.1001/
archoto.2009.24.
105. Hirayama T, Ito Y.A new view of the etiology of naso­pharyngeal carcinoma. Prev Med. 1981;10(5):614–
22. https://doi.org/10.1016/0091- 7435(81)90051- 7.
106. Shi W, Pataki I, MacMillan C, et al. Molecular pathology parameters in human nasopharyngeal car­cinoma. Cancer. 2002;94(7):1997–2006. https://doi.
org/10.1002/cncr.0679.
107. Zhang M, Li J, Shen G, etal. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with con­ventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–95. https://doi.
org/10.1016/j.ejca.2015.08.006.
108. Su S, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012;82(1):327–33.
https://doi.org/10.1016/j.ijrobp.2010.09.011.
109. Hao S, Tsang N, Chang C.Salvage surgery for recur­rent nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2002;128(1):63. https://doi.
org/10.1001/archotol.128.1.63.
110. Chan K, Woo J, King A, etal. Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyn­geal cancer. N Engl J Med. 2017;377(6):513–22.
https://doi.org/10.1056/nejmoa1701717.
111. Ji M, Huang Q, Yu X, etal. Evaluation of plasma Epstein-Barr virus DNA load to distinguish naso­pharyngeal carcinoma patients from healthy high-risk populations in Southern China. Cancer. 2014;120(9):1353–60. https://doi.org/10.1002/
cncr.28564.
112. Na’ara S, Amit M, Billan S, Cohen J, Gil Z.Outcome of patients undergoing salvage surgery for recur­rent nasopharyngeal carcinoma: a meta-analysis. Ann Surg Oncol. 2014;21(9):3056–62. https://doi.
org/10.1245/s10434- 014- 3683- 9.
113. Chen M, Wen W, Guo X, et al. Endoscopic naso­pharyngectomy for locally recurrent nasopharyngeal carcinoma. Laryngoscope. 2009;119(3):516–22.
https://doi.org/10.1002/lary.20133.
114. Chen M, Wang S, Zhu Y, et al. Use of a posterior pedicle nasal septum and oor mucoperiosteum ap to resurface the nasopharynx after endoscopic naso­pharyngectomy for recurrent nasopharyngeal carci­noma. Head Neck. 2011;34(10):1383–8. https://doi.
org/10.1002/hed.21928.
115. You R, Zou X, Hua Y, etal. Salvage endoscopic naso­pharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1–T3 nasopharyngeal carcinoma—a case-matched comparison. Radiother Oncol. 2015;115(3):399–
406. https://doi.org/10.1016/j.radonc.2015.04.024.
116. Frazell E, Lewis J. Cancer of the nasal cavity and accessory sinuses. A report of the management of 416 patients. Cancer. 1963;16(10):1293–301. https://doi.
org/10.1002/1097-0142(196310)16:10<1293::aid- cnc r2820161010>3.0.co;2- 4.
117. Ketcham A, Wilkins R, Van Buren J, Smith R. A combined intracranial facial approach to the para­nasal sinuses. Am J Surg. 1963;106(5):698–703.
https://doi.org/10.1016/0002- 9610(63)90387- 8.
118. Dulguerov P, Jacobsen M, Allal A, Lehmann W, Calcaterra T. Nasal and paranasal sinus car­cinoma: are we making progress? Cancer. 2001;92(12):3012–29. https://doi.org/10.1002/1097-
0142(20011215)92:12<3012::aid­cncr10131>3.0.co;2- e.
119. Banhiran W, Casiano R. Endoscopic sinus surgery for benign and malignant nasal and sinus neoplasm. Curr Opin Otolaryngol Head Neck Surg. 2005;13(1):50–4. https://doi.
org/10.1097/00020840- 200502000- 00012.
120. Snyderman C, Carrau R, Kassam A, etal. Endoscopic skull base surgery: principles of endonasal onco­logical surgery. J Surg Oncol. 2008;97(8):658–64.
https://doi.org/10.1002/jso.21020.
121. Schneider J, Burgner J, Webster R, Russell P.Robotic surgery for the sinuses and skull base. Curr Opin Otolaryngol Head Neck Surg. 2013;21(1):11–6.
https://doi.org/10.1097/moo.0b013e32835bc650.
122. Brennan P, Ammar M, Matharu J. Contemporary management of benign parotid tumours—the increasing evidence for extracapsular dissection. Oral Dis. 2016;23(1):18–21. https://doi.org/10.1111/
odi.12518.
123. Brennan P, Herd M, Howlett D, Gibson D, Oeppen R.Is ultrasound alone sufcient for imaging super­cial lobe benign parotid tumours before surgery? Br J Oral Maxillofac Surg. 2012;50(4):333–7. https://
doi.org/10.1016/j.bjoms.2011.01.018.
124. Thoeny H. Imaging of salivary gland tumours. Cancer Imaging. 2007;7(1):52–62. https://doi.
org/10.1102/1470- 7330.2007.0008.
125. Kendi A, Magliocca K, Corey A, et al. Is there a role for PET/CT parameters to characterize benign, malignant, and metastatic parotid tumors? Am J Roentgenol. 2016;207(3):635–40. https://doi.
org/10.2214/ajr.15.15590.
19 Updates andControversies intheManagement ofHead andNeck Malignancy
481
126. Sood A, Houlton J, Nguyen S, Gillespie M. Facial nerve monitoring during parotidectomy: a system­atic review and meta-analysis. Otolaryngol Head Neck Surg. 2014;151(1_Suppl):P56. https://doi.org
/10.1177/0194599814541627a86.
127. Guntinas-Lichius O, Eisele D.Facial nerve monitor­ing. In: Salivary gland neoplasms. Basel: Karger;
2016. p.46–52. https://doi.org/10.1159/000442124.
128. Krishnatreya M, Sharma J, Kataki A, Kalita M. Survival in carcinoma of unknown primary to neck nodes treated with neck dissection and radio­therapy. Ann Med Health Sci Res. 2014;4(8):165.
https://doi.org/10.4103/2141- 9248.138050.
129. Keller L, Galloway T, Holdbrook T, etal. p16 status, pathologic and clinical characteristics, biomolecu­lar signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown pri­mary. Head Neck. 2014;36(12):1677–84. https://doi.
org/10.1002/hed.23514.
130. Motz K, Qualliotine J, Rettig E, Richmon J, Eisele D, Fakhry C.Changes in unknown primary squamous cell carcinoma of the head and neck at initial pre­sentation in the era of human papillomavirus. JAMA Otolaryngol Head Neck Surg. 2016;142(3):223.
https://doi.org/10.1001/jamaoto.2015.3228.
131. Axelsson L, Nyman J, Haugen-Cange H, et al. Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection. J Otolaryngol Head Neck Surg. 2017;46(1) https://doi.org/10.1186/
s40463- 017- 0223- 1.
132. Sivars L, Näsman A, Tertipis N, etal. Human papil­lomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med. 2014;3(2):376–84.
https://doi.org/10.1002/cam4.19.
133. Vent J, Haidle B, Wedemeyer I, etal. p16 Expression in carcinoma of unknown primary: diagnos­tic indicator and prognostic marker. Head Neck. 2013;35(11):1521–6. https://doi.org/10.1002/
hed.23190.
134. Perkins S, Spencer C, Chernock R, et al. Radiotherapeutic management of cervical lymph node metastases from an unknown primary site. Arch Otolaryngol Head Neck Surg. 2012;138(7):656.
https://doi.org/10.1001/archoto.2012.1110.
135. Mistry R, Qureshi S, Talole S, Deshmukh S.Cervical lymph node metastases of squamous cell carcinoma from an unknown primary: outcomes and patterns of failure. Indian J Cancer. 2008;45(2):54. https://doi.
org/10.4103/0019- 509x.41771.
136. Huang C, Tseng F, Yeh T, et al. Prognostic fac­tors of unknown primary head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2008;139(3):429–35. https://doi.org/10.1016/j.
otohns.2008.05.015.
137. Christiansen H, Hermann R, Martin A, Nitsche M, Schmidberger H, Pradier O. Neck lymph node metastases from an unknown primary tumor.
Strahlenther Onkol. 2005;181(6):355–62. https://
doi.org/10.1007/s00066- 005- 1338- 2.
138. Aslani M, Sultanem K, Voung T, Hier M, Niazi T, Shenouda G.Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site: is there a need for neck dissection? Head Neck. 2007;29(6):585–
90. https://doi.org/10.1002/hed.20581.
139. Su AI, Welsh JB, Sapinoso LM, etal. Molecular clas­sication of human carcinomas by use of gene expres­sion signatures. Cancer Res. 2001;61(20):7388–93.
140. Golub T, Slonim D, Tamayo P, etal. Molecular clas­sication of cancer: class discovery and class pre­diction by gene expression monitoring. Science. 1999;286(5439):531–7. https://doi.org/10.1126/
science.286.5439.531.
141. Kato S, Krishnamurthy N, Banks K, et al. Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res. 2017;77(16):4238–46. https://doi.
org/10.1158/0008- 5472.can- 17- 0628.
142. Paderno A, Piazza C, Nicolai P. Recent advances in surgical management of parapharyngeal space tumors. Curr Opin Otolaryngol Head Neck Surg. 2015;23(2):83–90. https://doi.org/10.1097/
moo.0000000000000134.
143. Chu F, De Berardinis R, Tagliabue M, Zorzi S, Bandi F, Ansarin M. The role of transoral robotic surgery for parapharyngeal space. J Craniofac Surg. 2020;31(1):117–20. https://doi.org/10.1097/
scs.0000000000005912.
144. O’Malley B Jr, Quon H, Leonhardt F, Chalian A, Weinstein G. Transoral robotic surgery for para­pharyngeal space tumors. ORL. 2010;72(6):332–6.
https://doi.org/10.1159/000320596.
145. Kyubo K, Dong JL.The updated AJCC/TNM stag­ing system (8th edition) for oral tongue cancer. Transl Cancer Res. 2019;8(Suppl 2):S164–6. https://
doi.org/10.21037/tcr.2019.01.02.
146. Jain K, Sikora A, Baxi S, Morris L. Synchronous cancers in patients with head and neck can­cer. Cancer. 2013;119(10):1832–7. https://doi.
org/10.1002/cncr.27988.
147. Birkeland A, Rosko A, Chinn S, Prince M, Sun G, Spector M. Prevalence and outcomes of head and neck versus non-head and neck second primary malignancies in head and neck squamous cell carci­noma: an analysis of the surveillance, epidemiology, and end results database. ORL. 2016;78(2):61–9.
https://doi.org/10.1159/000443768.
148. Hanamoto A, Takenaka Y, Shimosegawa E, et al. Limitation of 2-deoxy-2-[F-18]uoro-d-glucose positron emission tomography (FDG-PET) to detect early synchronous primary cancers in patients with untreated head and neck squamous cell cancer. Ann Nucl Med. 2013;27(10):880–5. https://doi.
org/10.1007/s12149- 013- 0765- x.
149. Suzuki H, Hasegawa Y, Terada A, etal. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in
482
B. H. Siddiquee
pharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2008;134(11):1191. https://doi.org/10.1001/
archotol.134.11.1191.
150. Martel M, Alemany L, Taberna M, et al. The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma. Oral Oncol. 2017;64:37–43. https://doi.org/10.1016/j.
oraloncology.2016.11.011.
151. Diaz D, Reis I, Weed D, Elsayyad N, Samuels M, Abramowitz M. Head and neck second pri­mary cancer rates in the human papillomavirus era: a population-based analysis. Head Neck. 2015;38(S1):E873–83. https://doi.org/10.1002/
hed.24119.
152. Ferlito A, Shaha A, Silver C, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL. 2001;63(4):202–7.
https://doi.org/10.1159/000055740.
153. Noij D, Martens R, Zwezerijnen B, etal. Diagnostic value of diffusion-weighted imaging and 18F-FDG­PET/CT for the detection of unknown primary head and neck cancer in patients presenting with cervical metastasis. Eur J Radiol. 2018;107:20–5. https://doi.
org/10.1016/j.ejrad.2018.08.009.
154. Lee J, Kim J, Roh J, etal. Detection of occult pri­mary tumors in patients with cervical metasta­ses of unknown primary tumors: comparison of 18F FDG PET/CT with contrast-enhanced CT or CT/MR imaging—prospective study. Radiology. 2015;274(3):764–71. https://doi.org/10.1148/
radiol.14141073.
155. Hermans R.Imaging in cervical nodal metastases of unknown primary. Cancer Imaging. 2011;11(1A):S9– S14. https://doi.org/10.1102/1470- 7330.2011.9004.
156. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480–508.
157. Becker M, Zbären P, Laeng H, Stoupis C, Porcellini B, Vock P. Neoplastic invasion of the laryn­geal cartilage: comparison of MR imaging and CT with histopathologic correlation. Radiology. 1995;194(3):661–9. https://doi.org/10.1148/
radiology.194.3.7862960.
158. Beitler J, Muller S, Grist W, etal. Prognostic accu­racy of computed tomography ndings for patients with laryngeal cancer undergoing laryngectomy. J Clin Oncol. 2010;28(14):2318–22. https://doi.
org/10.1200/jco.2009.24.7544.
159. Becker M, Burkhardt K, Dulguerov P, Allal A. Imaging of the larynx and hypopharynx. Eur J Radiol. 2008;66(3):460–79. https://doi.
org/10.1016/j.ejrad.2008.03.027.
160. Thompson C, St. John M, Lawson G, Grogan T, Elashoff D, Mendelsohn A. Diagnostic value of sentinel lymph node biopsy in head and neck can­cer: a meta-analysis. Eur Arch Otorhinolaryngol. 2012;270(7):2115–22. https://doi.org/10.1007/
s00405- 012- 2320- 0.
161. Colnot D, Nieuwenhuis E, van den Brekel M, etal. Head and neck squamous cell carcinoma: US-guided
ne-needle aspiration of sentinel lymph nodes for improved staging—initial experience. Radiology. 2001;218(1):289–93. https://doi.org/10.1148/radiol-
ogy.218.1.r01dc01289.
162. Turner R, Hansen N, Stern S, Giulino A.Intraoperative examination of the sentinel lymph node for breast carcinoma staging. Am J Clin Pathol. 1999;112(5):627–34. https://doi.org/10.1093/
ajcp/112.5.627.
163. Koopal S, Tiebosch A, Albertus Piers D, Plukker J, Schraffordt Koops H, Hoekstra H. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer. 2000;89(8):1720–5. https://doi.
org/10.1002/1097- 0142(20001015)89:8<1720::aid­cncr11>3.0.co;2- f.
164. Höft S, Maune S, Muhle C, etal. Sentinel lymph­node biopsy in head and neck cancer. Br J Cancer. 2004;91(1):124–8. https://doi.org/10.1038/
sj.bjc.6601877. Accessed 8 Jun 2004.
165. Kuo P, Sosa J, Burtness B, et al. Treatment trends and survival effects of chemotherapy for hypopha­ryngeal cancer: analysis of the National Cancer Data Base. Cancer. 2016;122(12):1853–60. https://doi.
org/10.1002/cncr.29962.
166. Timmermans A, van Dijk B, Overbeek L, et al. Trends in treatment and survival for advanced laryn­geal cancer: a 20-year population-based study in The Netherlands. Head Neck. 2015;38(S1):E1247–55.
https://doi.org/10.1002/hed.24200.
167. Elicin O, Nisa L, Dal Pra A, etal. Up-front neck dis­section followed by denitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: ratio­nale, complications, toxicity rates, and oncological outcomes—a systematic review. Radiother Oncol. 2016;119(2):185–93. https://doi.org/10.1016/j.
radonc.2016.03.003.
168. Mehanna H, Wong W-L, McConkey CC, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374(15):1444–54. https://doi.org/10.1056/
NEJMoa1514493.
169. Miller M, Goldenberg D. AHNS series: do you know your guidelines? Principles of surgery for head and neck cancer: a review of the National Comprehensive Cancer Network guidelines. Head Neck. 2016;39(4):791–6. https://doi.org/10.1002/
hed.24654.
170. Woolgar J, Triantafyllou A. A histopathological appraisal of surgical margins in oral and oropha­ryngeal cancer resection specimens. Oral Oncol. 2005;41(10):1034–43. https://doi.org/10.1016/j.
oraloncology.2005.06.008.
171. Ch’ng S, Corbett-Burns S, Stanton N, etal. Close margin alone does not warrant postoperative adju­vant radiotherapy in oral squamous cell carci­noma. Cancer. 2013;119(13):2427–37. https://doi.
org/10.1002/cncr.28081.
172. Cohen E, Karrison T, Kocherginsky M, etal. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and
19 Updates andControversies intheManagement ofHead andNeck Malignancy
483
neck cancer. J Clin Oncol. 2014;32(25):2735–43.
https://doi.org/10.1200/jco.2013.54.6309.
173. Zhong L, Zhang C, Ren G, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and uorouracil followed by surgery versus up-front surgery inlocally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31(6):744–51. https://doi.org/10.1200/
jco.2012.43.8820.
174. Lee L, Huang C, Liao C, et al. Human papil­lomavirus- 16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One. 2012;7(7):e40767. https://doi.org/10.1371/journal.
pone.0040767.
175. Chung C, Zhang Q, Kong C, et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014;32(35):3930–8. https://doi.org/10.1200/
jco.2013.54.5228.
176. Stransky N, Egloff AM, Tward AD, etal. The muta­tional landscape of head and neck squamous cell car­cinoma. Science. 2011;333(6046):1157–60. https://
doi.org/10.1126/science.1208130.
177. Adelstein D. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concur­rent chemotherapy. J Clin Oncol. 2002;20(5):1405–
10. https://doi.org/10.1200/jco.20.5.14.
178. Chevalier D, Laccourreye O, Laccourreye H, Brasnu D, Piquet J.Cricohyoidoepiglottopexy for glottic car­cinoma with xation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients. Ann Otol Rhinol Laryngol. 1997;106(5):364–9.
https://doi.org/10.1177/000348949710600502.
179. McCoul E, Har-El G. Meta-analysis of impaired vocal cord mobility as a prognostic factor in T2 glottic carcinoma. Arch Otolaryngol Head Neck Surg. 2009;135(5):479. https://doi.org/10.1001/
archoto.2009.47.
180. Tham I, Lu J.Controversies and challenges in the current management of nasopharyngeal cancer. Expert Rev Anticancer Ther. 2010;10(9):1439–50.
https://doi.org/10.1586/era.10.97.
181. Chan A, Teo P, Johnson P. Controversies in the management of locoregionally advanced nasopharyngeal carcinoma. Curr Opin Oncol. 1998;10(3):219–25. https://doi.
org/10.1097/00001622- 199805000- 00008.
182. Kozakiewicz P, Grzybowska-Szatkowska L, Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carci-
noma. Oncol Lett. 2018;15(5):7497–505. https://doi.
org/10.3892/ol.2018.8300. Accessed 20 Mar 2018.
183. Argiris A, Karamouzis M, Raben D, Ferris R. Head and neck cancer. Lancet. 2008;371(9625):1695–709.
https://doi.org/10.1016/s0140- 6736(08)60728- x.
184. Alsaab H, Sau S, Alzhrani R, etal. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immu­notherapy: mechanism, combinations, and clini­cal outcome. Front Pharmacol. 2017;8 https://doi.
org/10.3389/fphar.2017.00561.
185. Vermorken J, Mesia R, Rivera F, et al. Platinum­based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.
https://doi.org/10.1056/nejmoa0802656.
186. Seiwert T, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open­label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65. https://doi.org/10.1016/
s1470- 2045(16)30066- 3.
187. Bauml J, Seiwert T, Pster D, etal. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35(14):1542–9. https://
doi.org/10.1200/jco.2016.70.1524.
188. Licitra L, Haddad R, Even C, etal. EAGLE: a phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squa­mous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15_Suppl):6012. https://doi.org/10.1200/
jco.2019.37.15_suppl.6012.
189. Lapidot T, Sirard C, Vormoor J, etal. A cell initiating human acute myeloid leukaemia after transplanta­tion into SCID mice. Nature. 1994;367(6464):645–
8. https://doi.org/10.1038/367645a0.
190. Campbell L, Polyak K. Breast tumor heterogene­ity: cancer stem cells or clonal evolution? Cell Cycle. 2007;6(19):2332–8. https://doi.org/10.4161/
cc.6.19.4914.
191. Elkashty O, Ashry R, Tran S.Head and neck can­cer management and cancer stem cells implication. Saudi Dent J. 2019;31(4):395–416. https://doi.
org/10.1016/j.sdentj.2019.05.010.
192. Clarke M, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124(6):1111–5. https://doi.
org/10.1016/j.cell.2006.03.011.
193. Zhang P, Zhang Y, Mao L, Zhang Z, Chen W. Side population in oral squamous cell carcinoma pos­sesses tumor stem cell phenotypes. Cancer Lett. 2009;277(2):227–34. https://doi.org/10.1016/j.
canlet.2008.12.015.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности